profiled CAFs in pancreatic cancer during in vivo tumor evolution, revealing that stromal transition to LRRC15+ myofibroblasts is a key determinant of poor response to anti‐PD‐L1 therapy.[225] Similarly, Krishnamurthy et al. This evidence concerns the gene LRRC15 and neoplasm.